Overall Fundamental outlook

|fundrankingplaceholder|
|techrankingplaceholder|

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Revenue projections:

Revenue projections for GLAND
Revenue projections for GLAND

The projected decline in Gland Pharma Limited's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 4.680000
forwardPE 25.312944
debtToEquity 2.738000
earningsGrowth 0.964000
revenueGrowth 0.223000
grossMargins 0.619670
operatingMargins 0.232020
trailingEps 62.310000
forwardEps 91.174690

GLAND's current ratio is 4.68, showing the company's capacity to service its short-term debt through its cash reserves and current assets. This is a positive indicator of liquidity, suggesting GLAND has no trouble covering its short-term financial obligations.
Gland Pharma Limited's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
Gland Pharma Limited's positive earnings and revenue growth indicate that the company is on track to expand its business. This growth suggests a strong financial outlook, with increasing profits and sales positioning Gland Pharma Limited for continued success in the market.
GLAND's positive gross and operating margins reflect its ability to generate profits from operations. These margins demonstrate efficient cost control and profitability, indicating strong financial health for the company.
Gland Pharma Limited's forward EPS being higher than its trailing EPS suggests that the company is expected to generate stronger profits this year. This points to improving financial performance, with Gland Pharma Limited anticipated to deliver better earnings than it did in the prior year.

Price projections:

Price projections for GLAND
Price projections for GLAND

Gland Pharma Limited's price projections have been revised higher over time, reflecting increased confidence in the company's future potential. This steady upward trend suggests analysts expect Gland Pharma Limited to continue its positive trajectory.

Insider Transactions:

Insider Transactions for GLAND
Insider Transactions for GLAND


GLAND had 5 sell transactions, while the market price was at 1913.4599853515624 per share.During the review period, no sell transactions were executed.With more buys than sells around GLAND's current price, there seems to be increased confidence among investors. This shift may indicate a favorable outlook, as the buying behavior suggests optimism for the stock's future growth or resilience.

Recommendation changes over time:

Recommendations trend for GLAND
Recommendations trend for GLAND


Recent analysis shows a strong buy bias for GLAND, encouraging investors to view it as a solid investment option. The positive sentiment surrounding GLAND suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.